Univercells Technologies, acquired in June 2023 by Donaldson, says that the Gene Therapy Program at the University of Pennsylvania (GTP) is expanding its evaluation agreement aimed at determining the scalability of GTP’s gene therapy product manufacturing using Univercells Technologies’ bioreactors.
GTP is an academic program led by James M. Wilson, MD, PhD, and focused on genetic medicines. Wilson serves as the Rose H. Weiss Professor and Director of the Orphan Disease Center and a professor of medicine and pediatrics at the Perelman School of Medicine.
GTP seeks to make gene therapies for rare diseases accessible worldwide. This agreement covers GTP’s evaluation of the commercial-series scale-X™ nitro 600 m2 bioreactor, with the goal of substantially increasing production per batch and potentially reducing cost of goods sold (COGS).
“We are honored to extend our collaborative work with GTP in evaluating the scalability of gene therapy production,” said Mathias Garny, general manager at Univercells Technologies.
“Our mission aligns closely with GTP’s vision of making gene therapies more accessible globally, and we are committed to supporting their efforts with our innovative bioprocessing technologies.”
Univercells Technologies developed the scale-X bioreactor with the support of the Bill and Melinda Gates Foundation’s Global Grand Challenge initiative. Originally designed to lower the cost of viral vaccine production for critical public health vaccines, the scale-X bioreactor is now being applied to enable viral vector accessibility for gene therapies.
![Univercells Technologies’ scale-X™ nitro 200 m2 and the scale-X nitro 600 m2, which is the instrument covered under the agreement between Univercells Technologies and the University of Pennsylvania Gene Therapy Program. [Univercells Technologies]](https://static.packgene.com/wp-content/uploads/2024/07/scale-X-nitro-200-600-w-logo-696x348-1.png "Univercells Technologies’ scale-X™ nitro 200 m2 and the scale-X nitro 600 m2, which is the instrument covered under the agreement between Univercells Technologies and the University of Pennsylvania Gene Therapy Program. [Univercells Technologies]"){kind=logo}
Univercells Technologies’ scale-X™ nitro 200 m2 and the scale-X nitro 600 m2, which is the instrument covered under the agreement between Univercells Technologies and the University of Pennsylvania Gene Therapy Program. [Univercells Technologies]
“Our hope is that Univercells Technologies will improve the efficiency of AAV vector manufacturing and help play a role in decreasing costs and enabling access through more affordable prices in the future,” said Wilson.
https://www.genengnews.com/topics/bioprocessing/univercells-technologies-and-upenn-expand-gene-therapy-partnership/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
[2024/11/15] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
One-time gene therapy reverses liver disease MASH in mouse models
Credit: Molecular Therapy (2024). DOI: 10.1016/j.ymthe.2024.10.023UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than...
PTC Therapeutics Achieves FDA Approval for First Brain-Administered Gene Therapy
Breakthrough Approval for Kebilidi The FDA has granted a landmark approval to PTC Therapeutics' Kebilidi, making it the first gene therapy in the U.S. to be administered directly into the brain. This approval represents a major step forward in gene therapy, offering...
FDA Approves Autolus’ New CAR-T Therapy for Aggressive Blood Cancer
In a significant development for cancer treatment, the US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ CAR-T cell therapy for adult patients with relapsed or treatment-resistant B cell precursor acute lymphoblastic leukemia (B-ALL). This...
Related Services
Plasmids GMP Services
AAV GMP Services
